NasdaqGS:ACRSPharmaceuticals
Aclaris Therapeutics (ACRS) Stock Drifts Lower As Losses Deepen On Thin Revenue
Aclaris Therapeutics stock slipped about 3% today, which looks mild compared with the strain running through its income statement. The headline from this quarter is the earnings drag, not the revenue line. Aclaris booked Q2 revenue of US$1.6 million yet reported a net loss of US$21.5 million, keeping earnings per share in loss territory at roughly US$0.15 per share.
For a clinical stage biotech, that scale of loss against such a small revenue base is what is driving sentiment now. The market...